Currently, treatments for bone metastases of malignant tumors mainly include comprehensive treatments such as analgesic therapy, radiation therapy, bone-modifying drug therapy, and surgery.

It's worth noting that Bayer has its own PSMA-targeting thorium-227 drug – BAY 2315497 – in phase 1 development, which uses an antibody for tumour targeting.

today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to 225 Ac-SSO110 (satoreotide) for the treatment of patients with Small Cell Lung Cancer ...

CHENGDU, China, March 26, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that the Company has received a clinical trial notice approving the ...

Compared with traditional external radiation therapy, the RDC drug SKB107 can benefit patients with systemic multiple bone metastases and is highly targeted, which can reduce the damage to normal ...